From lab to market: pHyph is now approved for launch in the EU
Bacterial vaginosis (BV), a common vaginal infection caused by an imbalance in the natural bacteria of the vagina, affects up to one in four women annually, often causing significant stress. Conventional antibiotic treatments typically prescribed by doctors can disrupt the natural vaginal microbiome, leading to high rates of recurrence and secondary yeast infections. Gedea Biotech’s novel antibiot
https://www.innovation.lu.se/en/article/lab-market-phyph-now-approved-launch-eu - 2025-12-19
